Trial Profile

A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK-3145095 (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors GlaxoSmithKline; GSK

12 Sep 2019 Status changed from recruiting to discontinued.
04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
07 Jan 2019 Planned number of patients changed from 220 to 30.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com